
**Reviewer’s Comments**



DEVELOPMENT AND IN VITRO EVALUATION OF **MATRIX**-TYPE TRANSDERMAL PATCHES OF LOSARTAN **POTASSIUM**

**ABSTRACT**

Since last decade drugs through skin hasreceived great attention of many researchers. The aim of present study was designed to develop a suitable matrix type transdermal drug delivery system (TDDS) of Losartan potassium using blends of different polymeric combinations of polyvinylpyrrolidone K30 (PVP K30) and ethylcellulose (EC), hydroxypropyl methyl cellulose and chitosan. Physical studies including thickness, folding endurance moisture content, tensile strength and flatness were performed on all formulations. In-vitro diffusion study of 10 hrs was performed by means of Franz diffusion cell. All theformulations were found to be suitable for formulating in terms of physicochemical characteristics. Stability study performed on selective batch, TP1 for 12 weeks at different temperatureindicates stability of transdermal patches at room temperature.

Present study concluded that Losartan potassium can be formulated into the transdermal matrix type patches to sustain its release characteristics. Polymeric composition of batch TP1 (PVP K30 : Chitosan:: 70:30) was found to be the best choice for manufacturing transdermal patches of Losartan potassium among the formulations studied.

**Keywords:** Losartan potassium, skin, transdermal drug delivery system,Franz diffusion cell,in-vitro diffusion.

**INTRODUCTION**Skin is an effective medium from which absorption of the drug takesplace and enters into systematic circulation over a period of time1. Transport of compounds via skin is considered to be a complex phenomenon, which allows the passage of certain chemicals into and across the skin. Transdermal drug delivery is the noninvasive delivery of medications from the surface of skin the largest and most accessible organ of human body through its layers, to the circulatory system2.

Transdermal patches are designed to slowly deliver the active substance(s) through the intact skin, resulting in a prolonged and adequately constant systemic absorptionrate, reduced number of doses and side effects of drug and improved therapeutic efficacy3.

At present scenario more than 74% of drugs are taken orally and are found not to be as valuable as desired. To advance such characters transdermal drug delivery system was introduced. A Transdermal patch is an adhesive patch that has a coating of drug that is placed on the skin to deliver specific dose into the systemic circulation over a period of time4.

Losartan potassium is an orally active angiotensin-II receptor antagonist used in the treatment of hypertension due to mainly blockade of AT1 receptor5,6,7.

In present work Losartan potassium was selected for development and evaluation of matrix-type transdermal patches in order to improve its bioavailabilityand reduce frequency of administration.

**MATERIALS AND METHODS**

Losartan potassium was obtained from BondChemical Industries Limited, Lagos, Polyvinylpyrrolidone K30 and HPMC K100 was received from Afrik Pharmaceuticals Limited, Nigeria. Ethyl cellulose, and Chitosan from Dana Drugs Limited, Nigeria. Castor oil, and propylene glycol was received from Food and Pharma Nig. Limited, Lagos, Nigeria. All other reagents used were of analytical grades.

**Preparation of the Losartan potassium transdermal patches**

Polymers in different ratio (table-1) were taken with plasticizerand Losartan potassium and dissolved in different solvents. Solution was then poured onto a glass petri dish and then placed in an oven. An inverted funnel was placed on the petri dish to facilitate the evaporation of the solvent at the controlled rate over the drying periods of 12 hrs at 40 °C. Thefilm thus formed was collected with a sharp razor blade8.

**Table-1: Compositions of the Losartan potassium transdermal patches**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Code** | **Polymers ratio (%)** | **Solvent** | **Plasticizer (20%)** | **Propylene glycol (Permeation enhancer)** |
| **TP1** | PVP K30 : Chitosan:: 70:30 | Dichloromethane (2% w/v) | Castor oil | 30% |
| **TP2** | PVP K30: Chitosan:: 30:70 | Dichloromethane (2% w/v) | Glycerine | - |
| **TP3** | HPMC: Ethyl cellulose::70:30 | Acetic acid (1 % w/v) | Castor oil | - |
| **TP4** | HPMC: Ethyl cellulose::30:70 | Acetic acid (1 % w/v) | Glycerine | 30% |

**EVALUATION OF TRANSDERMAL PATCHES**

**Determination of patch thickness**Patch thickness of Losartan potassium transdermal patches was measured using a digital micrometer (Mitutoyo, Japan). A mean of three readings was obtained9.

**Weight Variation:** Uniformity of weights of Losartan potassium transdermal patches were determined by weighing five matrices of each formulation. Aftereach film unit was weighed individually on a digital balance, the average weight of film was taken as the weight of the film10.

**Evaluation of drug content**

A known area of each patch was weighed accurately and dissolved in 2 ml chloroform  
followed by dilution with distilled water and then filtered. Drug content was analyzed by UV  
spectrophotometer (PerkinElmer, USA) at 250 nm. A drug-free film was usedas control. A  
mean of three readings was recorded. The results are reported as mean of six readings11.

**Folding Endurance:**

Three Losartan potassium transdermal patches of each batch were taken for this study. Folding endurance was determined by repeatedly folding one film at the same place till it break. The number of times the film could be folded at the same place without breakinggave the value of folding endurance12.

**Flatness**

Longitudinal strips of 1.8 cm in length were used out from the prepared Losartan potassium transdermal patches and then variation in the lengthsdue to the non-uniformity in flatness was measured13.

Flatness was calculated by measuring constriction of strips and a zero percent constriction was considered to be equal to a hundred percent flatness.  
Constriction (%) =(l1¬ – l2 )/( l2 ) X100

Where, l1 = final length of each strip, and l2 = initial length

**Determination of tensile strength**

The tensile strength of Losartan potassium transdermal patches was evaluated using Instron 4204 Tensile tester, with a 50 KN load cell (Instron, UK). Six samples of each formulation were tested at an extension speed of 5 mm/min14. The test was carried out at 25 ± 2 °C and 56 ± 2 % RH and tensile strength calculated –

τ=(Lmax )/(Ai )

Where τ is the tensile strength; Lmax is the maximum load; and Ai is the initial cross sectional area of the sample.

**Measurement of moisture content**

Each patch was weighed and kept in a desiccator containing fused calcium chloride at 40 °C for 24 h. The patches were reweighed until a constant weight was obtained. A mean of three readings was taken15. The results are reported as mean of six readings.

% Moisture content =(Initial Weight – Final Weight )/( Initial Weight) X100

**Water vapor transmission rate:**

Glass vials of 5 ml capacity were washed thoroughly and dried to a constant weight in an oven. About 2 g of fused calcium chloride was taken in the vials and the polymer films of 2.25 cm2 were fixed over the brim with the help of an adhesive tape. Then the vials were weighed and stored in a humidity chamber of 80-90 % RH condition for a period of 24 h 7, 23. The vials were removed and weighed at 24 h time intervals to note down the weight gain16.

WVTR =(Final Weight – Initial Weight )/( Time x Area ) X100

**Table-2: Physical Characterization of Losartan potassium transdermal patches**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **TP1** | **TP2** | **TP3** | **TP4** |
| **Physical Appearance** | Uniform, opaque, slightly sticky, flexible | Uniform, opaque, slightly sticky, flexible | Uniform, transluscent, slightly sticky, flexible | Uniform, transluscent, slightly sticky, flexible |
| **Thickness (mm)** | 0.30 ± 0.37 | 0.31 ± 0.27 | 0.32 ± 0.08 | 0.33 ± 0.09 |
| **Weight (mg)** | 45.3 ± 0.28 | 43.7 ± 0.34 | 42.3 ± 0.26 | 46.57 ± 0.13 |
| **% Drug content** | 96.77± 0.31 | 95.42± 0.18 | 96.42± 0.42 | 94.81± 0.12 |
| **Folding endurance** | > 288 | > 285 | > 122 | > 150 |
| **Flatness** | 100% | 100% | 100% | 100% |
| **Tensile strength (MPa)** | 4.39± 0.58 | 5.21± 0.32 | 6.37± 0.43 | 5.47± 0.09 |
| **% Moisture Content** | 3.44 ± 0.25 | 2.56 ± 0.26 | 2.78 ± 0.25 | 2.88 ± 0.25 |
| **WVTR (g/cm2/hrs** | 1.621x10-4± 0.12 | 1.489 x10-4± 0.27 | 1.543x10-4±0.08 | 1.443x10-4± 0.12 |

**In vitro diffusion study**

The diffusion studies of Losartan potassium transdermal patches were done to get an idea of permeation of drug through barrier from the transdermal system17. Franz-diffusion cell which is also called Keshary – Chein cellwas used to study the in-vitro release profile for a 10 hrs study. The cell consisted of sampling port and temperature maintaining jacket18. The outlet and inlet was connected with latex tube so the jacket had stagnant water inside and heat was provided by hot plate. Receptor compartment, which was maintained at 370C. The patches of diameter of 2 cm. Every hour 1 ml of the receptor fluid was withdrawn and replaced with 1 ml of fresh drug free buffer (pH 7.4) solution to maintain constant volume. Thewithdrawn sample was analyzed spectrophotometrically at 250 nm.

**Figure-1: *In-vitro* diffusion profile of Losartan potassium transdermal patches**

**Stability Study:**

The transdermal patches of Losartan potassium were subjected toaccelerated stability study at (40°C/75% RH) conditions for 90 days. The patches were packed in aluminum foil and kept at accelerated conditions. The patches were analyzed for drug content at 0, 30, 60 and 90 days respectively by a UV spectrophotometer method19.

**Statistical analysis**the results obtained were treated statistically using one-way analysis of variance (ANOVA).

Post-hoc Tukey-HSD (Honestly Significant Difference) test wasperformed when there was a  
statistically significant difference, which was set at p ≤ 0.05.

**Figure 2: Stability study of optimized Losartan potassium transdermal patches of batch TP1**

**RESULTS AND DISCUSSION**

Four transdermal patches formulations of Losartan potassiumwere prepared by using different polymers i.e. PVP K30, EC, chitosan, HPMC in different ratio. Dichloromethane (2% w/v) and acetic acid (1 % w/v) were used as the solvent based on the solubility of the polymers. Propylene glycol (30%) was used as permeation enhancer. Thickness lies in the range of 0.30 to 0.33 mm. Average thickness was almost uniform within same formulation a small variation in thickness was observed with different formulations. Thevariations in thickness may be due to viscosity of polymer solutions of different formulations. Patch thickness should also be appropriate because increased film thickness will increase compaction and reduce the mobility of molecules, which can decrease drug release from the patch20. Mean drug content of in all the patches was found to be greater than 94.81 %. The weight of patches lies in the range of 42.3 to 46.57 mg (table 2).

The % drug content lies in the range of 93.81 to 96.77. Content uniformity studies proved that the amount of Losartan potassiumin each patch of 2.009 cm2 was found to be fairly uniform.

Percent moisture content was found to be in the range of 2.56 to 3.44. Moisture  
content depend on type and concentration of plasticizer21. In present study castor oil and glycerin were used as plasticizer. Since patch with too much of water is prone to microbial growth while too less amount of water is prone to cracking and chances to absorb water from our skin22. Therefore, it is important to perform physicochemical studies in order to determine the suitable patch therapy over longer period of time without losing integrity of the polymeric composition of the transdermal patches. The folding endurance represents the elasticity of the patches. Formulation of batches TP1 and TP2 has shown higher folding enduarance (greater than 280) reason may be elastic nature of chitosan present in these two batches. Thistest is performed to check the suitability of sample to withstand folding and brittleness23.

Tensile strength lies in the range of 4.39-6.37 MPa. According to American Society for Testing Materials (ASTM), materials with tensile strength > 4.0 MPa possess an elastic characteristic24. Patches should be elastic in order to withstand external forces such as wear and tear during handling, storage or use. Water vapor transmission rate was found tobe maximum for formulation of batch TP1. The in-vitro diffusion of Losartan potassiumtransdermal patches formulation was studied using locally fabricated Franz diffusion cell. The cumulative percent drug release after 10 hrs in between 38.41 to 80.41%. Largest in batch code TP1 (80.41%) indicates the effects of propylene glycol as permeation enhancer. Rapid drug leakage was observed during the initial phase. However, after that a slow release occurred. In general the release of the drug depends upon hydrophobic and insoluble nature of thepolymers used25. The drug release increases on increasing the concentration of hydrophilic polymer in the polymer matrix. Drug release increased with increase in the content of PVP K30 due to the hydrophilicity of PVP K30 which facilitates water absorption thus promoting drug dissolution and drug release from the patch. Furthermore, as PVP leaches out, pores are created in the matrix for drug to diffuse out of the patch; thus, drug release is increased.

Stability studies performed on optimized formulations TP1 shows 97.62% drug content at refrigeration condition, 92.52% drug content at oven condition and 98.43% drug content at room temperature during the studies performed for 12 weeks (figure 2). Hence it is concluded from the obtained data that the optimum storage condition for transdermalpatches was found to be room temperature.

**CONCLUSION**

Transdermal drug delivery systems continue to deliver patients’ increased compliance by providing predictable and reliable therapeutic dosages. The prepared transdermal drug delivery system of Losartan potassiumusing different polymers such as HPMC, EC, Chitosan and PVP had shown good promising result for all the evaluated parameters. Based on the in-vitro drug release and drug content, formulation TP1 was concluded as an optimized formulation.

The studies concluded that proper combination of hydrophilic and hydrophobic polymers is  
required in formulation development of transdermal patches ofLosartan potassium.  
However, further in vivo and in vitro investigations are required.

**REFERENCES**

1. Rajabalaya R, Khanam J, Nanda A. Design of a matrix patch formulation for long-acting permeation of diclofenac potassium. *Asian J Pharm. Sci*. 2008; 3(1): 30-39.
2. Francis DJE, Development and evaluation of matrix type transdermal patches of pioglitazone hydrochloride, *Univ. J. Pharm. Res*. 2016, 1 (1), 10, 31-37.
3. Soler L, Boix A, Lauroba J, Colom H, Domenech J. Transdermal delivery of alprazolam from a monolithic patch: formulation based on in vitro characterization. *Drug Dev. Ind. Pharm*. 2012; 38(10):1171–1178.
4. Shinde AJ, Shinde AL, More HN: Design and evaluation transdermal drug  
   delivery system of gliclazide. *Asian J. Pharm*. 2010, 4(2):121–129.
5. Sica DA, Gehr TW, Ghosh S. Clinical pharmacokinetics of losartan. *Clin Pharmacokinet*. 2005, 44 (8): 797–814.
6. Boersma C, Atthobari J, Gansevoort RT, Annemans LJ, Postma MJ. "Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implications for decision making". *Pharmaco Economics*. 2006, 24 (6): 523–35.
7. Rang HP, Dale MM, Ritter JM, Moore PK. Pharmacology 5th ed. Edinburg; Churchill Livingstone. 2003, 203-14
8. Wokovich AM, Prodduturi S, Doub WH, Hussain AS. Transdermal drug delivery system adhesion as a critical safety, efficacy and quality attribute. *Eur. J. Pharm. Biopharm*. 2006, 64: 1-8.
9. Fauth C, Wiedersberg S, Neubert RN, Dittgen M. Adhesive backing foil interactions affecting the elasticity, adhesion strength of laminates, and how to interpret these properties of branded transdermal patches. *Drug Dev. Ind. Pharm*. 2002; 10: 1251-1259.
10. Umar S, Onyekachi MK. Development and evaluation of transdermal gel of Lornoxicam, *Univ. J. Pharm. Res*. 2017, 2(1), 17-20.
11. Ganju K, Kondalkar A, Pathak AK. Formulation and evaluation of transdermal patch of colchicines with release modifiers. The Pharmacist. 2007; 2(2): 21-23.
12. Mohamed A, Yamin S, Asgar A. Matrix type transdermal drug delivery systems of metoprolol tartrate: *in vitro* characterization. *Acta Pharm*. 2003, 53(2):119–125.
13. Elsaied HE, Dawaba HM, Ibrahim EA, Afouna MI. Investigation of proniosomes gel as a promising carrier for transdermal delivery of Glimepiride. *Univ. J. Pharm. Res*. 2016, 1(2), 1-18.
14. Wang C, Han W, Tang X, Zhang H. Evaluation of drug release profile from patches based on styrene–isoprene–styrene block copolymer: the effect of block structure and plasticizer. *AAPS Pharm. Sci. Tech*. 2012;13:556–67.
15. Cilurzo F, Gennari CG, Minghetti P. Adhesive properties: a critical issue in transdermal patch development. *Expert Opin. Drug Deliv*. 2012; 9:33–45.
16. Park MC, Lee MC. Effects of polymeric emulsifiers on the properties of acrylic emulsion pressure-sensitive adhesives. *J. Appl. Polym. Sci*. 2004; 94:1456–60.
17. Lee PJ, Ahmad N, Langer R, Mitragotri S. Evaluation of chemical enhancers in the transdermal delivery of lidocaine*. Int. J. Pharm*. 2006; 308: 33-39.
18. Taghizadeh SM, Soroushnia A, Mirzadeh H, Barikani M. Preparation and *in vitro* evaluation of a new fentanyl patch based on acrylic/silicone pressure-sensitive adhesive blends. *Drug Dev. Ind. Pharm*. 2009, 35(4), 487–498.
19. Qvist MH, Hoeck U, Kreilgaard B, Madsen F, Frokjaer S. Release of chemical permeation enhancers from drug-in-adhesive transdermal patches. *Int. J. Pharm*. 2002, 231( 2), 253–263.
20. Pichayakorn W, Suksaeree J, Boonme P, Amnuaikit T, Taweepreda W, Ritthidej GC. Nicotine transdermal patches using polymeric natural rubber as the matrix controlling system: efect of polymer and plasticizer blends. *J. Memb. Sci*. 2012, 411, 81–90.
21. Mautalik S, Udupa N. Design and evaluation of glipizide transdermal patches. *J. Pharm. Pharmceut. Sci*. 2012; 8(1): 26-38.
22. Selvam P. Design and evaluation of transdermal drug delivery of ketotifen fumarate,  
    Int. J. Pharm. *Biomed. Res*. 2010; 1(2): 42-7**.**
23. Aquil M, Sultana Y, Ali A. Matrix type transdermal drug delivery systems of metoprolol  
    tarterate: In-vitro characterization. *Acta Pharma*. 2003; 53(2): 119-5.
24. Madhura S, Sheelpriya DR, Ittadwar MA. Development and characterization of transdermal patches of Ondansetron hydrochloride. *Int. J. Pharm. and Pharm. Sci*. 2012, 4 (5).
25. Maghraby GM. Transdermal delivery of hydrocortisone from eucalyptus oil microemulsion: Effects of cosurfactants. *Int. J. Pharm*. 2008; 355: 285-292.